Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 861–870 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 861
- Medicine slug
- linagliptin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
100 hours
- Numeric value
- 100
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1da67d4-51e0-41b7-9fe1-7f38c0d1baa1 (opens source in a new tab)
Linagliptin label
Version not recorded · Effective date not recorded
Plasma concentrations of linagliptin decline in at least a biphasic manner with a long terminal half-life (>100 hours), related to the saturable binding of linagliptin to DPP-4.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c797ea5c-cab7-494b-9044-27eba0cfe40f (opens source in a new tab)
Linagliptin label
Version not recorded · Effective date not recorded
Plasma concentrations of linagliptin decline in at least a biphasic manner with a long terminal half-life (>100 hours), related to the saturable binding of linagliptin to DPP-4.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfe327e8-f6ab-41e5-bdef-d520118cd83a (opens source in a new tab)
Linagliptin label
Version not recorded · Effective date not recorded
Plasma concentrations of linagliptin decline in at least a biphasic manner with a long terminal half-life (>100 hours), related to the saturable binding of linagliptin to DPP-4.
Projected row 862
- Medicine slug
- linagliptin
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
99%
- Numeric value
- 99
- Unit
- %
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1da67d4-51e0-41b7-9fe1-7f38c0d1baa1 (opens source in a new tab)
Linagliptin label
Version not recorded · Effective date not recorded
Plasma protein binding of linagliptin is concentration-dependent, decreasing from about 99% at 1 nmol/L to 75%-89% at ≥30 nmol/L, reflecting saturation of binding to DPP-4 with increasing concentration of linagliptin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c797ea5c-cab7-494b-9044-27eba0cfe40f (opens source in a new tab)
Linagliptin label
Version not recorded · Effective date not recorded
Plasma protein binding of linagliptin is concentration-dependent, decreasing from about 99% at 1 nmol/L to 75%-89% at ≥30 nmol/L, reflecting saturation of binding to DPP-4 with increasing concentration of linagliptin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfe327e8-f6ab-41e5-bdef-d520118cd83a (opens source in a new tab)
Linagliptin label
Version not recorded · Effective date not recorded
Plasma protein binding of linagliptin is concentration-dependent, decreasing from about 99% at 1 nmol/L to 75%-89% at ≥30 nmol/L, reflecting saturation of binding to DPP-4 with increasing concentration of linagliptin.
Projected row 863
- Medicine slug
- linagliptin
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
1.5 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1da67d4-51e0-41b7-9fe1-7f38c0d1baa1 (opens source in a new tab)
Linagliptin label
Version not recorded · Effective date not recorded
After oral administration of a single 5 mg dose to healthy subjects, peak plasma concentrations of linagliptin occurred at approximately 1.5 hours post dose (T max ); the mean plasma area under the curve (AUC) was 139 nmol*h/L and maximum concentration (C max ) was 8.9 nmol/L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c797ea5c-cab7-494b-9044-27eba0cfe40f (opens source in a new tab)
Linagliptin label
Version not recorded · Effective date not recorded
After oral administration of a single 5 mg dose to healthy subjects, peak plasma concentrations of linagliptin occurred at approximately 1.5 hours post dose (T max ); the mean plasma area under the curve (AUC) was 139 nmol*h/L and maximum concentration (C max ) was 8.9 nmol/L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfe327e8-f6ab-41e5-bdef-d520118cd83a (opens source in a new tab)
Linagliptin label
Version not recorded · Effective date not recorded
After oral administration of a single 5 mg dose to healthy subjects, peak plasma concentrations of linagliptin occurred at approximately 1.5 hours post dose (T max ); the mean plasma area under the curve (AUC) was 139 nmol*h/L and maximum concentration (C max ) was 8.9 nmol/L.
Projected row 864
- Medicine slug
- lincomycin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
5.4 ± 1.0 hours
- Numeric value
- 5.4
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c01906fa-2c73-4c13-9765-2fd06628d263 (opens source in a new tab)
Lincomycin label
Version not recorded · Effective date not recorded
The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20c0e8af-a78f-47f8-ace4-06b80def7003 (opens source in a new tab)
Lincomycin label
Version not recorded · Effective date not recorded
The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2b5be20-cc6f-4221-9d3e-3f8b5886cd05 (opens source in a new tab)
Lincomycin label
Version not recorded · Effective date not recorded
The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebabccf4-f082-4fc0-9223-f4826dc89b13 (opens source in a new tab)
Lincomycin label
Version not recorded · Effective date not recorded
The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7692968-7ac8-48ab-89a4-27c7803e31f4 (opens source in a new tab)
Lincomycin label
Version not recorded · Effective date not recorded
The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61f4851d-d919-400d-912a-05eb9dca11d4 (opens source in a new tab)
Lincomycin label
Version not recorded · Effective date not recorded
The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23f9608c-3126-35db-e063-6294a90af054 (opens source in a new tab)
Lincomycin label
Version not recorded · Effective date not recorded
The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7efe038a-8d67-4151-864a-b4863b46643e (opens source in a new tab)
Lincomycin label
Version not recorded · Effective date not recorded
The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75e149cc-b668-427e-bae7-a0d215e4fb7a (opens source in a new tab)
Lincomycin label
Version not recorded · Effective date not recorded
The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd2838b7-f8c9-4049-a306-ea620a9c0fe2 (opens source in a new tab)
Lincomycin label
Version not recorded · Effective date not recorded
The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours.
Projected row 865
- Medicine slug
- linezolid
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 36
- Source count
- 36
- Agreement rate
- 1
- Recorded readings
100%
- Numeric value
- 100
- Unit
- %
- Source records
- 36
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 36 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b721756c-3b5e-456d-a2f6-0d8a56cc7f35 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c401f1a8-cc37-461b-bfef-f2e156629bf8 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a89a37ec-a736-464b-a83a-84bef6ccd702 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d05541c6-fd63-cc99-e053-2995a90a4ec7 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7402aa01-50de-46c8-a341-d30da5b32b1c (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dff6eec-8662-335f-e063-6294a90ab159 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bef116a8-427d-4855-86de-0017e01430b0 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:217f3ee2-2534-4c32-8e9d-09b6d65df4af (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e0d868d-f419-47e8-a3bc-41ececac468b (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a287cdf4-47a8-459f-8890-86181af5e836 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3c55eb4-50f2-47f0-a424-5a6779518e1d (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b239458e-9a3e-49ac-9ac7-a4badc53dff6 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d1b4d0a-0fd9-448b-a28f-51ed05a5a0cf (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:561abed1-c0f9-40ee-98a8-7c710bcde822 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf4fa35d-93c9-41c3-a2ae-0298014b8a9f (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90dd8c13-c428-4472-91e5-5b1fcdc4fce3 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9ac1ad7-7a23-463d-a467-f0ecc7e523e7 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74f035ec-a0b1-4371-a17b-20b0b11864c9 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc3e3ea4-50aa-49ee-a8bc-fb48bfc8e014 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a04bdc9-d6f0-4e35-b683-a472a2e4ff04 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab1b4ab5-7338-4b01-963b-43eeb4c9cf1c (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83a84897-ccca-42a1-ab1a-bbf1d43a982b (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0c75e79-bf29-4f1d-a45d-ae28398a52d9 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:870c9600-04d5-4b44-a5b5-02252a310f22 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fedbffa7-087d-4448-85c9-0350a3947080 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16007ca5-7956-4414-af38-406a6623400e (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc12bd87-5ef0-4ebe-bc00-cbd7896ce08c (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95b8fd63-d018-8062-e053-2995a90ab96d (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7368298b-d75c-4950-bbc1-00fc53f472ec (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e5e9975-6f36-42e4-ab46-0e75dda83592 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2220c753-e0e8-4797-bce2-34b3c63bd631 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e70e63b-bfd5-478d-a8ee-8ba22c9efabd (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efe6818c-b798-4d1d-8196-6447a305ad71 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce57225b-4580-442b-8c48-8045297cbb50 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca930576-62ab-4af5-ac3e-27ca376baca6 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:374af2a7-d994-40bd-a86a-cd9038d0b72c (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.
Projected row 866
- Medicine slug
- linezolid
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 36
- Source count
- 36
- Agreement rate
- 1
- Recorded readings
31%
- Numeric value
- 31
- Unit
- %
- Source records
- 36
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 36 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b721756c-3b5e-456d-a2f6-0d8a56cc7f35 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c401f1a8-cc37-461b-bfef-f2e156629bf8 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a89a37ec-a736-464b-a83a-84bef6ccd702 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d05541c6-fd63-cc99-e053-2995a90a4ec7 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7402aa01-50de-46c8-a341-d30da5b32b1c (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dff6eec-8662-335f-e063-6294a90ab159 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bef116a8-427d-4855-86de-0017e01430b0 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:217f3ee2-2534-4c32-8e9d-09b6d65df4af (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e0d868d-f419-47e8-a3bc-41ececac468b (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a287cdf4-47a8-459f-8890-86181af5e836 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3c55eb4-50f2-47f0-a424-5a6779518e1d (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b239458e-9a3e-49ac-9ac7-a4badc53dff6 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d1b4d0a-0fd9-448b-a28f-51ed05a5a0cf (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:561abed1-c0f9-40ee-98a8-7c710bcde822 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf4fa35d-93c9-41c3-a2ae-0298014b8a9f (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90dd8c13-c428-4472-91e5-5b1fcdc4fce3 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9ac1ad7-7a23-463d-a467-f0ecc7e523e7 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74f035ec-a0b1-4371-a17b-20b0b11864c9 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc3e3ea4-50aa-49ee-a8bc-fb48bfc8e014 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a04bdc9-d6f0-4e35-b683-a472a2e4ff04 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab1b4ab5-7338-4b01-963b-43eeb4c9cf1c (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83a84897-ccca-42a1-ab1a-bbf1d43a982b (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0c75e79-bf29-4f1d-a45d-ae28398a52d9 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:870c9600-04d5-4b44-a5b5-02252a310f22 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fedbffa7-087d-4448-85c9-0350a3947080 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16007ca5-7956-4414-af38-406a6623400e (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc12bd87-5ef0-4ebe-bc00-cbd7896ce08c (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95b8fd63-d018-8062-e053-2995a90ab96d (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7368298b-d75c-4950-bbc1-00fc53f472ec (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e5e9975-6f36-42e4-ab46-0e75dda83592 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2220c753-e0e8-4797-bce2-34b3c63bd631 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration- independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e70e63b-bfd5-478d-a8ee-8ba22c9efabd (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efe6818c-b798-4d1d-8196-6447a305ad71 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce57225b-4580-442b-8c48-8045297cbb50 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca930576-62ab-4af5-ac3e-27ca376baca6 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:374af2a7-d994-40bd-a86a-cd9038d0b72c (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The plasma protein binding of linezolid is approximately 31% and is concentration-independent.
Projected row 867
- Medicine slug
- linezolid
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 36
- Source count
- 36
- Agreement rate
- 1
- Recorded readings
40 to 50 liters
- Numeric value
- 40
- Unit
- L
- Source records
- 36
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 36 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b721756c-3b5e-456d-a2f6-0d8a56cc7f35 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c401f1a8-cc37-461b-bfef-f2e156629bf8 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a89a37ec-a736-464b-a83a-84bef6ccd702 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d05541c6-fd63-cc99-e053-2995a90a4ec7 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7402aa01-50de-46c8-a341-d30da5b32b1c (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dff6eec-8662-335f-e063-6294a90ab159 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bef116a8-427d-4855-86de-0017e01430b0 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:217f3ee2-2534-4c32-8e9d-09b6d65df4af (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e0d868d-f419-47e8-a3bc-41ececac468b (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a287cdf4-47a8-459f-8890-86181af5e836 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3c55eb4-50f2-47f0-a424-5a6779518e1d (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b239458e-9a3e-49ac-9ac7-a4badc53dff6 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d1b4d0a-0fd9-448b-a28f-51ed05a5a0cf (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:561abed1-c0f9-40ee-98a8-7c710bcde822 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf4fa35d-93c9-41c3-a2ae-0298014b8a9f (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90dd8c13-c428-4472-91e5-5b1fcdc4fce3 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9ac1ad7-7a23-463d-a467-f0ecc7e523e7 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74f035ec-a0b1-4371-a17b-20b0b11864c9 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc3e3ea4-50aa-49ee-a8bc-fb48bfc8e014 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a04bdc9-d6f0-4e35-b683-a472a2e4ff04 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab1b4ab5-7338-4b01-963b-43eeb4c9cf1c (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83a84897-ccca-42a1-ab1a-bbf1d43a982b (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0c75e79-bf29-4f1d-a45d-ae28398a52d9 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:870c9600-04d5-4b44-a5b5-02252a310f22 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fedbffa7-087d-4448-85c9-0350a3947080 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16007ca5-7956-4414-af38-406a6623400e (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc12bd87-5ef0-4ebe-bc00-cbd7896ce08c (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95b8fd63-d018-8062-e053-2995a90ab96d (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7368298b-d75c-4950-bbc1-00fc53f472ec (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e5e9975-6f36-42e4-ab46-0e75dda83592 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2220c753-e0e8-4797-bce2-34b3c63bd631 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e70e63b-bfd5-478d-a8ee-8ba22c9efabd (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efe6818c-b798-4d1d-8196-6447a305ad71 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce57225b-4580-442b-8c48-8045297cbb50 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca930576-62ab-4af5-ac3e-27ca376baca6 (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:374af2a7-d994-40bd-a86a-cd9038d0b72c (opens source in a new tab)
Linezolid label
Version not recorded · Effective date not recorded
The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.
Projected row 868
- Medicine slug
- liothyronine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 27
- Source count
- 26
- Agreement rate
- 1
- Recorded readings
2 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 26
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 26 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38ef3766-bb9a-402e-9e4a-ad8bb5b26e4c (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0dcec611-2b7a-4cf3-80c3-7389be2f0a94 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7efdd16d-37e6-4dc8-a6c5-5b42c4813379 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b0f2db9-642d-d84f-b102-b43de34bbe75 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31a11006-8122-49fc-8769-a28a359ac526 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52baac91-4b00-40d4-9ca7-8b9405bd415c (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21002702-422b-1402-73b8-670314d8e579 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c97dc9ec-af73-4836-aa0d-c27e66e792a9 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c54cf95f-6465-4203-b98b-a54ba5a26843 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d6b6f92-89e8-497a-ab23-d0afa2137d1f (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51452b31-ff68-4e0c-b982-c15502ebf1d3 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f882d34f-6b9f-4d9d-8a3e-3054ba91c506 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1133ebe8-38c2-2505-e063-6294a90aaa2f (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db65bcd8-e9c9-4095-9975-03be1f443823 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b18e24fd-def0-4ff4-aa08-5f91c03c6f9e (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:548d684a-86f5-4e57-9844-d8cf0a84e068 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2 to 1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actionsthrough control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ababc2ad-0458-663e-e053-2a95a90a5a86 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4fb09346-3d30-4a7c-a97c-480d5924997a (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:892e63ef-3a60-45fa-b12b-d6795acc0956 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5222f13d-7222-4845-b863-49e7558f5b1a (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d3633e3-44b7-4f62-9fe4-e5c7c4129345 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26cf6872-f4d4-41dd-8957-a000f13efbb3 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20cbf84d-80f2-4b94-ad47-6aaa362fb4d0 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76fa4eb6-fefa-4e97-9543-f81e465743e6 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57744c7c-af44-4bc4-a5a8-79f05710f469 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:115a84c2-0126-4dd7-816e-1873875f1e49 (opens source in a new tab)
Liothyronine label
Version not recorded · Effective date not recorded
The biological half-life is about 2-1/2 days. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.
Projected row 869
- Medicine slug
- liraglutide
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 21
- Source count
- 21
- Agreement rate
- 1
- Recorded readings
55%
- Numeric value
- 55
- Unit
- %
- Source records
- 21
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 21 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b898330-eca1-f60a-71d2-b91716e336ed (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2bfc30a-8392-4255-a4d8-fa0b8d1659b2 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35e613e3-7aae-4152-b827-99d1ee7841be (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a36f43f-d734-97cc-e063-6294a90ae0da (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2100ec49-57b2-4330-ab5f-057ce9b7e4d0 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a372465-d56b-2b80-e063-6394a90a3304 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0450d8a2-a88e-4849-9788-ed4f5246f223 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b11f6ac-4c27-4748-9e65-22d4cf3adfb4 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14bf9812-14ee-46ce-93b1-686e4906cbbc (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:625ac780-70a9-41e4-a892-bcba0f803f1c (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a36b801-41e2-2eed-e063-6294a90a6f27 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a9ef4ea-c76a-4d34-a604-27c5b505f5a4 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d18f106-0584-4fee-97ab-32771a64b809 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fe557ae-4ff0-47a2-8ec3-37bb0fbdcc64 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb032379-043b-443c-d552-b5d25f27f3c4 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3946d389-0926-4f77-a708-0acb8153b143 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4253be3b-bda6-4efd-8118-9c9538168a88 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0efc3a89-211a-4496-baab-e8265e07de2b (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb66a46c-9019-4a98-8e5d-581109facfba (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22c86976-9657-4dd0-8fff-0c3f3f08357c (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ba917f7-b974-4364-a745-7494ecae3e73 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
Projected row 870
- Medicine slug
- liraglutide
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 21
- Source count
- 21
- Agreement rate
- 1
- Recorded readings
13 hours
- Numeric value
- 13
- Unit
- hours
- Source records
- 21
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 21 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b898330-eca1-f60a-71d2-b91716e336ed (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 0.9 to 1.4 L/h with an elimination half-life of approximately 13 hours, making liraglutide suitable for once daily administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2bfc30a-8392-4255-a4d8-fa0b8d1659b2 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 0.9 to 1.4 L/h with an elimination half-life of approximately 13 hours, making liraglutide suitable for once daily administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35e613e3-7aae-4152-b827-99d1ee7841be (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 1.2 L/h with an elimination half-life of approximately 13 hours, making VICTOZA suitable for once daily administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a36f43f-d734-97cc-e063-6294a90ae0da (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Unlike native GLP-1, liraglutide is stable against metabolic degradation by both peptidases and has a plasma half-life of 13 hours after subcutaneous administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2100ec49-57b2-4330-ab5f-057ce9b7e4d0 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Elimination The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 1.2 L/h with an elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a372465-d56b-2b80-e063-6394a90a3304 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Unlike native GLP-1, liraglutide is stable against metabolic degradation by both peptidases and has a plasma half-life of 13 hours after subcutaneous administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0450d8a2-a88e-4849-9788-ed4f5246f223 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Elimination The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 1.2 L/h with an elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b11f6ac-4c27-4748-9e65-22d4cf3adfb4 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 0.9-1.4 L/h with an elimination half-life of approximately 13 hours, making liraglutide suitable for once daily administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14bf9812-14ee-46ce-93b1-686e4906cbbc (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Elimination The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 1.2 L/h with an elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:625ac780-70a9-41e4-a892-bcba0f803f1c (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 0.9 to 1.4 L/h with an elimination half-life of approximately 13 hours, making liraglutide suitable for once daily administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a36b801-41e2-2eed-e063-6294a90a6f27 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Unlike native GLP-1, liraglutide is stable against metabolic degradation by both peptidases and has a plasma half-life of 13 hours after subcutaneous administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a9ef4ea-c76a-4d34-a604-27c5b505f5a4 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Elimination The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 1.2 L/h with an elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d18f106-0584-4fee-97ab-32771a64b809 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 1.2 L/h with an elimination half-life of approximately 13 hours, making VICTOZA suitable for once daily administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fe557ae-4ff0-47a2-8ec3-37bb0fbdcc64 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Elimination The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 1.2 L/h with an elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb032379-043b-443c-d552-b5d25f27f3c4 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Elimination The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 1.2 L/h with an elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3946d389-0926-4f77-a708-0acb8153b143 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 0.9 to 1.4 L/h with an elimination half-life of approximately 13 hours, making liraglutide suitable for once daily administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4253be3b-bda6-4efd-8118-9c9538168a88 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Elimination The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 1.2 L/h with an elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0efc3a89-211a-4496-baab-e8265e07de2b (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Elimination The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 1.2 L/h with an elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb66a46c-9019-4a98-8e5d-581109facfba (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Elimination The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 1.2 L/h with an elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22c86976-9657-4dd0-8fff-0c3f3f08357c (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 0.9 to 1.4 L/h with an elimination half-life of approximately 13 hours, making liraglutide suitable for once daily administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ba917f7-b974-4364-a745-7494ecae3e73 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Elimination The mean apparent clearance following subcutaneous administration of a single-dose of liraglutide is approximately 1.2 L/h with an elimination half-life of approximately 13 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=860Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.